Pharma marketers enter 2026 asking where DTC fits in the DTP era. That question, which few foresaw 12 months ago, reflects the fast rise of direct-to-patient programs. The programs are changing how patients access medicines—and how patients hear about medicines could therefore evolve to reflect the emerging sales channel.
Galapagos’ last asset posts mixed results as future remains in flux
Galapagos is flush with billions in cash, but it’s not moving forward with its own pipeline. So what’s the Belgian biotech going to do with